ACE in COPD: A therapeutic target?

Thorax

Volumn 58, Issue 7, 2003, Pages 556-558

  Forth, R ^a   Montgomery, H ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ERYTHROPOIESIS; HUMAN; LONG TERM CARE; LUNG FUNCTION; LUNG VASCULAR RESISTANCE; OXYGENATION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0038015369     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.58.7.556     Document Type: Review

References (37)

1. Danser AH, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995;92:1387-8.
2. Reneland R, Haenni A, Andersson PE, et al. Skeletal muscle angiotensin-converting enzyme and its relationship to blood pressure in primary hypertension and healthy elderly men. Blood Press 1999;8:16-22.
3. Schling P, Mallow H, Trindl A, et al. Evidence for a local renin angiotensin system in primary cultured human preadipocytes. Int J Obes Relat Metab Disord 1999;23:336-41.
4. Zhuo J, et al. Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptors. J Hypertens 1998;16:2027-37.
5. Costerousse O, Allegrini J, Lopez M, et al. Angiotensin-I converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J 1993;290:33-40.
6. Lazarus DS, Aschoff J, Fanburg BL, et al. Angiotensin converting enzyme (kininase II) mRNA production and enzymatic activity in human peripheral blood monocytes are induced by GM-CSF but not by other cytokines. Biochim Biophys Acta 1994;1226:12-8.
7. Guba M, Steinbauer M, Buchner M, et al. Differential effects of short-term ACE- and AT1-receptor inhibition on postischemic injury and leukocyte adherence in vivo and in vitro. Shock 2000;13:190-6.
8. Constantinescu CS, Goodman DB, Ventura ES. Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells. Immunol Lett 1998;62:25-31.
9. Constantinescu CS, Ventura E, Hilliard B, et al. Effects of the angiotensin converting enzyme inhibitor captopril on experimental autoimmune encephalomyelitis. Immunopharmacol Immunotoxicol 1995;17:471-91.
10. Krootila K, Oksala O, Von Dickhoff K, et al. Effect of captopril on ocular irritative response to topical neutral formaldehyde and YAG-laser capsulotomy in the rabbit. J Ocul Pharmacol Ther 1995;11:243-52.
11. Weber KT. Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. Semin Nephrol 1997;17:467-91.
12. Dietze G, Wicklmayr M, Bottger I, et al. The kallikrein-kinin system and muscle metabolism: biochemical aspects. Agents Actions 1980;10:335-8.
13. Jauch KW, Hartl WH, Georgieff M, et al. Low-dose bradykinin infusion reduces endogenous glucose production in surgical patients. Metabolism 1988;37:185-90.
14. Wicklmayr M, Dietze G, Gunther B, et al. The kallikrein-kinin system and muscle metabolism: clinical aspects. Agents Actions 1980;10:339-43.
15. DeWitt LM, Putney JW Jr. Stimulation of glycogenolysis in hepatocytes by angiotensin II may involve both calcium release and calcium influx. FEBS Lett 1983;160:259-63.
16. Reisenleiter F, Katz N, Gardemann A. Control of hepatic carbohydrate metabolism and haemodynamics in perfused rat liver by arterial and portal angiotensin II. Eur J Gastroenterol Hepatol 1996;8:279-86.
17. Messerli FH, Nowaczynski W, Honda M, et al. Effects of angiotensin II on steroid metabolism and hepatic blood flow in man. Circ Res 1977;40:204-7.
18. Bataineh A, Raij L. Angiotensin II, nitric oxide, and end-organ damage in hypertension. Kidney Int Suppl 1998;68:14-9.
19. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol 1999;31:51-60.
20. Cody RJ. The integrated effects of angiotensin II. Am J Cardiol 1997;79:9-11.
21. Kanazawa H, Hirata K, Yoshikawa J. Effects of captopril administration on pulmonary hemodynamics and tissue oxygenation during exercise in ACE gene subtypes in COPD patients: a preliminary study. Thorax 2003;58:629-31.
22. Kanazawa H, Okamoto T, Hirata K, et al. Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:1235-8.
23. Kanazawa H, Otsuka T, Hirata K, et al. Association between the angiotensin-converting enzyme gene polymorphisms and tissue oxygenation during exercise in patients with COPD. Chest 2002;121:697-701.
24. Marshall RP, Webb S, Bellingan GJ, et al. Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med 2002;166:646-50.
25. Woods DR, Pollard AJ, Collier DJ, et al. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene and arterial oxygen saturation at high altitude. Am J Respir Crit Care Med 2002;166:362-6.
26. Lam SY, Leung PS. A locally generated angiotensin system in rat carotid body. Regul Pept 2002;107:97-103.
27. Coirault C, Hagege A, Chemla D, et al. Angiotensin-converting enzyme inhibitor therapy improves respiratory muscle strength in patients with heart failure. Chest 2001;119:1755-60.
28. Abraham MR, Olson LI, Joyner MJ, et al. Angiotensin-converting enzyme genotype modulates pulmonary function and exercise capacity in treated patients with congestive stable heart failure. Circulation 2002;106:1794-9.
29. Cargill RI, Lipworth BJ. Lisinopril attenuates acute hypoxic pulmonary vasoconstriction in humans. Chest 1996;109:424-9.
30. Nong Z, Stassen JM, Moons L, et al. Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling. Circulation 1996;94:1941-7.
31. Glicklich D, Kapoian T, Mian H, et al. Effects of erythropoietin, angiotensin II, and angiotensin-converting enzyme inhibitor on erythroid precursors in patients with posttransplantation erythrocytosis. Transplantation 1999;68:62-6.
32. Williams AG, Rayson MP, Jubb M, et al. The ACE gene and muscle performance. Nature 2000;403:614.
33. Woods DR, World M, Rayson MP, et al. Endurance enhancement related to the human angiotensin I-converting enzyme I-D polymorphism is not due to differences in the cardiorespiratory response to training. Eur J Appl Physiol 2002;86:240-4.
34. Montgomery HE, Marshall R, Hemingway H, et al. Human gene for physical performance. Nature 1998;393:221-2.
35. Woods DR, Brull D, Montgomery HE. Endurance and the ACE I/D polymorphism. Sci Prog 2000;B3:317-36.
36. Zhang B, Tanaka H, Shono N, et al. The I allele of the angiotensin-converting enzyme gene is associated with an increased percentage of slow-twitch type I fibers in human skeletal muscle. Clin Genet 2003;63:139-44.
37. Pasha MA, Khan AP, Kumar R, et al. Variations in angiotensin-converting enzyme gene insertion/deletion polymorphism in Indian populations of different ethnic origins. J Biosci 2002;27:67-70.